Indaptus Therapeutics, Inc.
| Metric | FY2021 | FY2020 |
|---|---|---|
| Research and development | $2.5M-5.0% | $2.7M |
| General and administrative | $5.2M+451.3% | $944K |
| Total operating expenses | $7.7M+114.7% | $3.6M |
| Loss from operations | -$7.7M-114.7% | -$3.6M |
| Other income, net | $18K+17.3% | $15K |
| Net loss | -$7.7M-115.2% | -$3.6M |
| Net loss available to common stockholders per share of common stock, basic and diluted | -$1.89-2.7% | -$1.84 |
| Weighted average number of shares used in calculating net loss per share, basic and diluted | $4090599.00+110.3% | $1944672.00 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
No Form 4 transactions on record.
Informational purposes only, not investment advice.